drugset / Trial / NCT02201251

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

NCT02201251

Phase 3 Completed 63 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupOpen-labelHealth-services research

Summary

The purpose of this study is to evaluate the safety of topiramate monotherapy compared with levetiracetam another standard antiepileptic drug (AED), as monotherapy for new-onset or recent-onset epilepsy (seizure disorder) on pediatric growth and maturation, bone mineralization, and kidney stone formation in children aged 2 to 15 years.

Timeline

Start
2014-10-06
Primary completion
2020-04-30
Completion
2020-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levetiracetam Other / unclassified 60 mg/kg
Comparator Levetiracetam Other / unclassified 3000 mg
Subject Topiramate Small molecule 350 mg
Subject Topiramate Small molecule 400 mg

Indications